Thalassemia



Complications in Children With B- Thalassemia Major


Condition:   Beta-thalassemia
Intervention:   Other: Demographic, physical examination, data will becollected .
Sponsor:   Assiut University
Not yet recruiting


A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)


Condition:   Transfusion Dependent Beta-thalassemia
Intervention:   Genetic: ST-400 Investigational product
Sponsors:   Sangamo Therapeutics;   Bioverativ Therapeutics Inc.
Recruiting


Colla Corii Asini Treating Anemia in Pregnant Women With Thalassemia(Presenting the Syndrome of Blood Deficiency)


Condition:   Thalassemia
Interventions:   Drug: Colla corii asini;   Drug: a Simulate Agent of Colla corii asini granule
Sponsor:   The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
Not yet recruiting


Quality of Life and Treatment Satisfaction in β-Thalassemia Patients Receiving Deferasirox


Condition:   β-thalassemia
Intervention:   Other: The Medical Outcomes Short-Form 36-Item Health Survey (SF-36v2) It
Sponsor:   Assiut University
Not yet recruiting


Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector


Condition:   Beta-Thalassemia
Intervention:   Genetic: Gene-modified autologous stem cells
Sponsor:   Shenzhen Geno-Immune Medical Institute
Not yet recruiting


A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia


Condition:   Thalassemia
Interventions:   Drug: Luspatercept;   Other: Placebo;   Other: Best Supportive Care (BSC)
Sponsors:   Celgene;   Acceleron Pharma, Inc.
Recruiting


Gene Therapy for Beta-Thalassemia Major Using Autologous Hematopoietic Stem Cell Genetically Modified


Condition:   Beta Thalassemia Major
Intervention:   Genetic: Autologous CD34+ cells genetically modified
Sponsors:   Nanfang Hospital of Southern Medical University;   Guangdong Yike Gene Science and Technology CO.,Ltd
Not yet recruiting


Long-term Safety and Efficacy Follow-up of Subjects Treated With GSK2696277 for Transfusion Dependent Beta-thalassemia in San Raffaele Telethon Institute of Gene Therapy-Beta Thalassemia (TIGET-BTHAL) Study


Condition:   Beta Thalassaemia
Intervention:   Other: Safety and Efficacy assessments
Sponsors:   GlaxoSmithKline;   San Raffaele Telethon Institute of Gene Therapy (SR-TIGET)
Recruiting


A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia


Condition:   Beta-Thalassemia
Intervention:   Drug: Bitopertin
Sponsor:   Hoffmann-La Roche
Recruiting


A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Subjects With Transfusion-Dependent β-Thalassemia, Who Have a β0/β0 Genotype


Condition:   Beta-Thalassemia
Intervention:   Genetic: LentiGlobin BB305 Drug Product
Sponsor:   bluebird bio
Recruiting


The Efficacy and Safety of HYDROXYUREA in Management of Beta Thalassemia Patients in Karachi Pakistan


Condition:   Thalassemia, Beta
Intervention:   Drug: Hydroxyurea
Sponsor:   Dr.Saqib Hussain Ansari
Recruiting


Adiponectin, IL-6 and hsC-RP in Relation to Carotid Intima-media Thickness in B-thalassemia Patients


Condition:   Thalassemia
Interventions:   Diagnostic Test: Interleukin-6;   Diagnostic Test: HsC-RP;   Diagnostic Test: Adiponectin level;   Diagnostic Test: Carotid intima media thickness
Sponsor:   Assiut University
Not yet recruiting


Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major


Condition:   Thalassemia Major
Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Mycophenolate mofetil;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Thymoglobulin;   Drug: Basiliximab
Sponsor:   First Affiliated Hospital of Guangxi Medical University
Recruiting


Evaluation of Nutritional Status in Thalassemia Major Patients in Assiut Children Hospital


Condition:   Thalassemia Major
Intervention:  
Sponsor:   Assiut University
Not yet recruiting


Monitoring of Chimerism After Transplantation in Patients With β Thalassemia Major and the Treatment Strategies for the Reduction of Chimerism


Condition:   Beta Thalassemia Major
Interventions:   Drug: Interleukin-2;   Drug: Donor Regulatory T-Lymphocytes
Sponsor:   First Affiliated Hospital of Guangxi Medical University
Recruiting


A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Subjects With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype


Condition:   Beta-Thalassemia
Intervention:   Genetic: LentiGlobin BB305 Drug Product
Sponsor:   bluebird bio
Recruiting


Effects of Spirulina on Cardiac Functions in Children With Beta Thalassemia Major


Condition:   Beta Thalassemia
Intervention:   Other: spirulina
Sponsor:   Tanta University
Active, not recruiting


Gene Therapy for Transfusion Dependent Beta-thalassemia


Condition:   Beta-Thalassemia
Intervention:   Genetic: Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene
Sponsors:   IRCCS San Raffaele;   Fondazione Telethon;   GlaxoSmithKline
Recruiting


Reproductive Capacity and Iron Burden in Thalassemia


Condition:   THALASSEMIA MAJOR
Interventions:   Other: Blood Draw/Semen Exam;   Other: Retrospective data/Chart Review/Relevant Clinical Results;   Other: Pituitary MRI
Sponsors:   Children's Hospital & Research Center Oakland;   Novartis Pharmaceuticals
Recruiting


ACE-536 Extension Study - Beta Thalassemia


Condition:   Beta-Thalassemia
Intervention:   Drug: ACE-536
Sponsor:   Acceleron Pharma, Inc.
Active, not recruiting


Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.


Condition:   Thalassemia Major
Intervention:   Drug: ruxolitinib
Sponsor:   Novartis Pharmaceuticals
Completed


Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia


Condition:   Non-transfusion Dependent Thalassemia
Intervention:   Drug: ICL670 deferasirox
Sponsor:   Novartis Pharmaceuticals
Active, not recruiting


Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.


Conditions:   Beta Thalassemia Major;   Beta Thalassemia Intermedia
Interventions:   Drug: Sotatercept 0.1mg/kg;   Drug: Sotatercept 0.3mg/kg;   Drug: Sotatercept 0.5mg/kg;   Drug: Sotatercept 0.75mg/kg;   Drug: Sotatercept 1.0mg/kg;   Drug: Sotatercept 1.5mg/kg
Sponsor:   Celgene
Active, not recruiting


Perceptions of Thalassemia Major in Singapore: An Exploratory Study of Stigma


Condition:   Thalassemia Major
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Completed


Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia


Condition:   Severe Thalassemia
Intervention:   Drug: Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan
Sponsors:   Washington University School of Medicine;   New England Research Institutes;   Pediatric Blood and Marrow Transplant Consortium
Completed

Refine Your Search Advanced Search